{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:46:21Z","timestamp":1787496381261,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA-05274"],"award-info":[{"award-number":["DA-05274"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T05:15:33Z","timestamp":1400649333000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Effects of methoxsalen, a CYP2A5\/6 inhibitor, on nicotine dependence behaviors in mice"],"prefix":"10.1016","volume":"85","author":[{"given":"Deniz","family":"Bagdas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pretal P.","family":"Muldoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2360-8361","authenticated-orcid":false,"given":"Andy Z.X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Imad","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.05.006_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ntr\/ntt105","article-title":"Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5\/6 inhibitor","volume":"16","author":"Alsharari","year":"2014","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jnci\/94.2.108","article-title":"Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans","volume":"94","author":"Benowitz","year":"2002","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/clpt.2008.3","article-title":"Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction","volume":"83","author":"Benowitz","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","article-title":"Nicotine chemistry, metabolism, kinetics and biomarkers","volume":"192","author":"Benowitz","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003495-200868080-00005","article-title":"Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status","volume":"68","author":"Buchhalter","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2014.05.006_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.106.111237","article-title":"Inhibition of nicotine metabolism by methoxysalen: pharmacokinetic and pharmacological studies in mice","volume":"320","author":"Damaj","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/jm049696n","article-title":"5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6","volume":"48","author":"Denton","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2009.19","article-title":"Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African\u2013American light smokers","volume":"85","author":"Ho","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.107.132977","article-title":"Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs","volume":"325","author":"Jackson","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.107.121616","article-title":"Nicotine dependence and reward differ between adolescent and adult male mice","volume":"322","author":"Kota","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.clpt.2006.02.006","article-title":"Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation","volume":"79","author":"Lerman","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1124\/jpet.113.208256","article-title":"Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4\/5)bgs-null mouse","volume":"347","author":"Li","year":"2013","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0022-3565(24)36947-2","article-title":"A\u00a0major role for CYP2A6 in nicotine C-oxidation by human liver microsomes","volume":"282","author":"Messina","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.105.004549","article-title":"Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes","volume":"33","author":"Murphy","year":"2005","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01677060802572887","article-title":"Nicotine dependence pharmacogenetics: role of genetic variation in nicotine metabolizing enzymes","volume":"23","author":"Ray","year":"2009","journal-title":"J.\u00a0Neurogenet."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mcp.2000.107651","article-title":"Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking","volume":"68","author":"Sellers","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/14622200310001615231","article-title":"The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in\u00a0vivo","volume":"5","author":"Sellers","year":"2003","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-006-0306-6","article-title":"Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5","volume":"184","author":"Siu","year":"2006","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00008571-200409000-00006","article-title":"Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians","volume":"14","author":"Schoedel","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.neuropharm.2014.05.006_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/dmd.112.048736","article-title":"Generation and characterization of a novel Cyp2a(4\/5)bgs-null mouse model","volume":"41","author":"Wei","year":"2013","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2014.05.006_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1248\/cpb.c12-00872","article-title":"Synthetic models related to methoxalen and menthofuran-cytochrome P450 (CYP) 2A6 interactions. benzofuran and coumarin derivatives as potent and selective inhibitors of CYP2A6","volume":"61","author":"Yamaguchi","year":"2013","journal-title":"Chem. Pharm. Bull. Tokyo"},{"key":"10.1016\/j.neuropharm.2014.05.006_bib22","first-page":"897","article-title":"Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in\u00a0vitro","volume":"29","author":"Zhang","year":"2001","journal-title":"Drug. Metab. Dispos."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:13:28Z","timestamp":1746216808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":22,"alternative-id":["S0028390814001737"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.006","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of methoxsalen, a CYP2A5\/6 inhibitor, on nicotine dependence behaviors in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}